Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling by Tang, WM et al.
Title
Elevated TAK1 augments tumor growth and metastatic
capacities of ovarian cancer cells through activation of NF-κB
signaling
Author(s) Cai, C; Shi, L; Liu, VWS; Tang, WM; Liu, J; Leung, THY; Chan,KKL; Yam, JWP; Yao, KM; Ngan, HYS; Chan, DW
Citation Oncotarget, 2014, v. 5 n. 17, p. 7549-7562
Issued Date 2014
URL http://hdl.handle.net/10722/205209
Rights Creative Commons: Attribution 3.0 Hong Kong License
Oncotarget7549www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 17
Elevated TAK1 augments tumor growth and metastatic 
capacities of ovarian cancer cells through activation of NF-κB 
signaling
Patty C.H. Cai1, Lei Shi2, Vincent W.S. Liu1, Hermit W.M. Tang1, Iris J. Liu1, Thomas 
H.Y. Leung1, Karen K.L. Chan1, Judy W.P. Yam3, Kwok-Ming Yao2, Hextan Y.S. 
Ngan1 and David W. Chan1
1 Department of Obstetrics and Gynaecology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, 
P.R.China
2 Department of Biochemistry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P.R.China
3 Department of Pathology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, P.R.China
Correspondence to: Hextan YS Ngan, email: hysngan@hku.hk
Correspondence to: David W Chan, email: dwchan@hku.hk
Keywords: TAK1, NF-κB signaling, ovarian cancer, high-grade tumor
Received: May 07, 2014 Accepted: July 26, 2014 Published: July 27, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Transforming growth factor (TGF)-β-activating kinase 1 (TAK1) is a serine/
threonine kinase which is frequently associated with human cancer progression. 
However, its functional role in tumorigenesis is still controversial. Here, we report that 
TAK1 enhances the oncogenic capacity of ovarian cancer cells through the activation 
of NF-κB signaling. We found that TAK1 is frequently upregulated and significantly 
associated with high-grade and metastatic ovarian cancers. Mechanistic studies 
showed that Ser412 phosphorylation is required for TAK1 in activating NF-κB signaling 
and promotes aggressiveness of ovarian cancer cells. Conversely, suppression of TAK1 
activity by point mutation at Ser412, RNAi mediated gene knockdown or TAK1 specific 
inhibitor ((5Z) -7-Oxozeaenol) remarkably impairs tumor growth and metastasis 
in ovarian cancer in vitro and in vivo. Our study underscores the importance of 
targeting TAK1 as a promising therapeutic approach to counteract the ovarian cancer 
progression. 
INTRODUCTION
Ovarian cancer is one of the leading causes of 
cancer death in females worldwide [1]. The high mortality 
rate of this disease is due to its late diagnosis and therefore 
poor prognosis as most cases present with aggressive 
ovarian cancer [2]. Despite advances in cancer treatment 
in the past decade, the cure rate of this disease remains 
modest [3]. Recent studies have revealed that personalized 
gene-targeted cancer therapy shows promising results 
in improving the survival and quality of life of patients 
suffering from aggressive tumors [4-7]. Therefore, a better 
understanding of the molecular mechanisms underlying 
ovarian cancer oncogenesis is urgently needed for guiding 
this therapeutic approach.
It is well-known that nuclear factor-kappa B 
(NF-κB) signaling pathway has multiple roles in 
cancer progression such as anti-apoptosis, cell cycle, 
angiogenesis and metastasis [8]. However, its mechanistic 
roles in human cancers are varied because it regulates 
the expression of over 400 genes that are simultaneously 
stimulated by multiple upstream regulators [9]. 
Degradation of IκBs through the proteasomal pathway 
after phosphorylation by IKKs activates NF-κB signaling 
activity. Thus, p-IKK and p-IκB can be monitored to 
reflect NF-κB signaling activity [10]. Previous studies 
have stated that blockage of NF-κB activity increases the 
efficiency of chemotherapy by cisplatin in ovarian cancer 
models [11] and suppresses ovarian cancer cell metastasis 
[12]. Hence, the NF-κB signaling pathway is a promising 
target in cancer therapy.
Transforming growth factor (TGF)-β-activating 
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kinase 1 (TAK1) is a serine/threonine kinase and a 
mitogen-activated protein kinase kinase kinase that can 
be activated by many upstream cytokines, such as TGF-
beta, IL-1beta, TNF-alpha, and toll-like receptor ligands 
[13]. Previous reports have shown that TAK1 may play 
diverse roles in various cancers by acting as tumor 
suppressor or oncoprotein. For instance, in liver cancer, 
ablation of TAK1 can cause hepatic injury, inflammation, 
fibrosis and carcinogenesis, which identifies TAK1 
as a tumor suppressor [14]. However, in skin tumors, 
pancreatic cancers and colon cancers, inhibition of TAK1 
up-regulates ROS, sensitizes cells to chemoresistance, 
and promotes apoptosis, respectively [15-17]. Indeed, 
the functional roles and molecular mechanisms of TAK1 
in ovarian cancers remain obscure. Effects of TAK1 are 
mediated via phosphorylation of multiple residues in its 
activation loop. Many phosphorylation sites had been 
previously identified, such as Ser-192, Thr178, Thr184/187 
and Ser412 [18-21] but only Thr184/Thr187 has been 
well studied in promonocytic leukemic and prostate 
cancer cells [22, 23]. However, which phosphorylated site 
required for TAK1 mediated NF-κB signaling in ovarian 
oncogenesis is still unclear.
In this study, we provide compelling evidence 
showing TAK1 is frequently overexpressed in aggressive 
and high-grade ovarian cancer. Importantly, TAK1 
activates NF-κB signaling activity through the increased 
phosphorylation at Ser412, and such activated TAK1/
NF-κB signaling cascade is indispensable in promoting 
ovarian cancer cell growth, anchorage independent 
growth ability, chemoresistance, as well as in vitro and 
in vivo metastasis in ovarian cancer. These results reveal 
mechanistic insights into the functional role of TAK1 
in NF-κB mediated ovarian cancer aggressiveness, 
suggesting TAK1 is a therapeutic target for this disease.
RESULTS
TAK1 is frequently upregulated in ovarian cancer
To understand the functional role and expression 
status of TAK1 in ovarian cancer, qPCR analysis was 
performed to evaluate the expression level of TAK1 
mRNA in ovarian cancer samples (n=88), normal ovaries 
Figure 1: TAK1 is upregulated in high-grade and metastatic ovarian cancer. (A) Q -PCR using MAP3K probe was performed 
for three times independently in normal cancer samples (n=48), ovarian cancer samples (n=88), HOSE cell lines (n=2) and ovarian cancer 
cell lines (n=6). The expression of TAK1 mRNA was normalized by internal control 18S gene. *P<0.01. (B) Representative IHC showed 
the staining intensity of TAK1 in borderline cystadenoma, serous low-grade and high-grade on an ovarian cancer tissue array (OVC1021) 
(x20). Increased immune-positive staining of TAK1 was observed along low- to high-grade ovarian cancers. (C) Western blot analysis using 
anti-TAK1, p-TAK1 at Ser412, IKK and p-IKK (Ser180/181) of 2 pairs of primary cultured cells from omentum (OMC) and ovary (OVC). 
The protein amount of loading was normalized by β-actin. 
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(n=48), normal ovarian HOSE cell lines (n=2) and ovarian 
cancer cell lines (n=6). The results showed that TAK1 was 
significantly upregulated in ovarian cancer samples by 
8-fold and ovarian cancer cell lines by 18-fold as compared 
with normal ovaries and ovarian HOSE cell lines, 
respectively (*P<0.01) (Figure 1A). Clinicopathological 
correlation indicated that overexpresson of TAK1 was 
remarkably associated with high-grade tumor formation 
(*P=0.033) (Supplementary Table 1). However, there was 
no significant association between TAK1 overexpression 
and other clinical parameters. Furthermore, Western 
blot and immunohistochemical analysis were conducted 
to evaluate the protein expression level of TAK1 in 
ovarian cancer cell lines and a commercial tissue array 
(OV1021, Pantomics) respectively. Results showed 
that the expression of TAK1 was obviously upregulated 
in ovarian cancer cell lines as compared to the HOSEs 
(Supplementary Figure S1). In addition, there is a 
progressive increase in TAK1 expression from low-
grade to high-grade serous ovarian cancers (Figure 1B). 
By clinicopathological correlation analysis, high TAK1 
expression was significantly correlated with high-grade 
tumor again (P=0. 001), in which 47.9% of high-grade 
tumor cases exhibited more than 6-fold overexpression of 
TAK1 whereas 85.4% of low-grade tumor cases showed 
lower expression of TAK1 (Supplementary Table 2). In 
addition, expression of TAK1 was highly correlated with 
cancer cell metastasis (P=0.025), in which 54% of cases 
demonstrated more than 6-fold overexpression of TAK1 
(Supplementary Table 2). Most of serous ovarian cancers 
are found to have omental metastasis [24]. This implies 
that the cancer cells from the omentum are considered 
more aggressive as compared from the cancer cells still 
contained within the ovary. Thus, we cultured the primary 
ovarian cancer cells from both omentum and ovary of 
the same ovarian cancer patient (n = 2). Western blot 
analysis showed that there was a remarkable upregulation 
of TAK1, p-TAK1 at Ser412 and p-IKK (Ser180/181) 
in primary ovarian cancer cells from omentum (OMC) 
as compared with primary ovarian cancer cells from the 
ovaries (OVC) (Figure 1C). The p-TAK1 (Ser412) and 
p-IKK (Ser180/181) represent the activities of TAK1 and 
NF-κB respectively. Therefore, this result supports the 
findings from clinicopathological analysis, suggesting 
that increased TAK1 and NF-κB signaling activities are 
involved in aggressive ovarian cancer cells.
TAK1 promotes ovarian cancer cell growth and 
anchorage independent growth ability 
Given that TAK1 was frequently overexpressed 
in ovarian cancer, in particular high-grade tumor, study 
of the functional role of TAK1 in ovarian cancer cells 
is very worthwhile. Stable TAK1-overexpressing clones 
were generated by transfection of TAK1 plasmids into 
ovarian cancer cell lines; OVCA429 (429-C12 and 429-
C13) and A2780cp (Acp-T2 and Acp-T3), while stable 
knockdown of endogenous TAK1 was achieved in SKOV3 
(SK-sh1-KD3 and SK-sh1-KD6) and A2780cp (Acp-sh1-
KD1 and Acp-sh2-KD10) cells using vector-based RNAi 
constructs (Figure 2A-B). By XTT cell proliferation assay, 
enforced expression of TAK1 in OVCA429 and A2780cp 
showed an average 5-fold and 2-fold, respectively, higher 
proliferation rate than their vector controls (*P<0.01) 
(Figure 2A). In contrast, depletion of TAK1 in SKOV3 
and A2780cp decreased the proliferation rate by ~30% 
and ~50%, respectively, when compared to their vector 
controls (*P<0.01) (Figure 2B). To further prove the 
importance of TAK1 in ovarian cancer cell growth, 
the specific TAK1 inhibitor, (5Z) -7-Oxozeaenol, was 
used to treat A2780cp and SKOV3 and the TAK1-over-
expressing OVCA429 clones 429-C12 and 429-C13. XTT 
cell proliferation assay showed that inhibitor treatment 
suppressed the proliferation of A2780cp, SKOV3, and 
both 429-C12 and 429-C13, by ~66%, ~75%, and ~80%, 
respectively, when compared with the untreated controls 
(*P<0.01) (Figure 2C). In addition, soft agar assay showed 
that enforced expression of TAK1 increased not only the 
size but also the number of colonies in Acp-T2 and Acp-T3 
by 1.5-fold and 1.2-fold, respectively (*P<0.01). On the 
other hand, depletion of TAK1 reduced both the size and 
number of colonies in SK-sh1-KD3 and SK-sh1-KD6 by 
~40% and ~70%, respectively, (*P<0.01) as compared 
with their vector controls (Figure 2D). Furthermore, 
focus formation assay demonstrated that the TAK1-over-
expressing clones in OVCA429 (429-C12 and 429-C13) 
and A2780cp (Acp-T2 and Acp-T3) exhibited more and 
larger colonies by ~1.5-fold and ~2-fold, respectively, 
when compared with their vector controls (*P<0.05) 
(Figure 2E). In contrast, the stable TAK1 knockdown 
clones in SKOV3 (SK-sh1-KD3 and SK-sh1-KD6) and 
A2780cp (Acp-sh1-KD1 and Acp-sh2-KD10) showed less 
and smaller colonies by ~50% and ~66%, respectively, as 
compared with their vector controls (*P<0.05) (Figure 
2F). Taken together, these results indicate that TAK1 is 
capable of promoting ovarian cancer cell growth and 
anchorage independence.
TAK1 increases tumor growth in vivo in ovarian 
cancer cells
In order to investigate the tumor forming capacity 
of TAK1 in ovarian cancer cells, the stable TAK1 
knockdown clone (Acp-sh1-KD1) and vector control of 
A2780cp were selected for subcutaneous injection into 
nude mice at each side of flank. Acp-sh1-KD1 exhibited 
reduced tumor growth rate by 60% when compared to 
the vector control (*P=0. 022) (Figure 2G). Western blot 
analysis confirmed that the tumor tissues from Acp-KD1-
treated mice expressed lower levels of TAK1, p-IKK and 
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Figure 2: TAK1 promotes ovarian cancer cell growth in vitro and in vivo. (A) Stable TAK1 over-expressing clones were 
established in OVCA429 and A2780cp cells. XTT cell proliferation assay demonstrated that TAK1 could remarkably increase cell 
proliferation in OVCA429 and A2790cp stable clones (*P<0.01). (B) TAK1 knockdown stable clones were established by shRNA in 
SKOV3 and A2780cp cells. Depletion of endogenous TAK1 reduced cell proliferation in SKOV3 and A2790cp stable clones (*P<0.01). 
(C) Treatment of TAK1 inhibitor, (5Z) -7-Oxozeaenol, (1.0 µM and 2.5 µM for 24 hours) significantly reduced cell proliferation in both 
ovarian cancer parental cell lines (A2780cp and SKOV3) (*P<0.01) and TAK1 stably over-expressing clones (429-C12 and 429-C13) 
(*P<0.01) dose dependently. (D) Soft agar assay showed that TAK1-expressing clones exhibited an increased number of colonies compared 
with the vector control (*P<0.01), whereas clones with depletion of TAK1 had less number of colonies as compared with the vector 
control (*P<0.01). Representative photos show the size of colonies under microscopy. (E) Enforced expression of TAK1 in OVCA429 and 
A2780cp significantly increased the number of cell colonies, (*P<0.05). (F) Depletion of TAK1 by shRNA knockdown in SKOV3 and 
A2780cp decreased the number of cell colonies (*P<0.05). (G) Stable TAK1 knockdown clone (Acp-sh1-KD1) showed a slower growth 
rate as compared with the vector control in nude mouse tumor xenograft model (*P=0. 022). Representative tumor picture was taken after 
sacrificed the nude mice on Day 21. Western blot analysis confirmed the expressions of TAK1, p-TAK1 at Ser412, p-IKK and IKK from 
the tumor tissues. (H) TAK1 inhibitor, (5Z) -7-Oxozeaenol (16mg/kg), significantly inhibited the tumor formation rate in nude mice as 
compared with the parental A2780cp cell control (*P=0. 049). The weight of the tumors treated with TAK1 inhibitor was approximately 
3-folds lower as compared with control group (*P=0. 015).
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p-TAK1 at Ser412 (Figure 2G). To further confirm TAK1 
in tumor growth of ovarian cancer cells, A2780cp cells 
expressing high levels of TAK1 were injected into nude 
mice subcutaneously in the presence and absence of (5Z) 
-7-Oxozeaenol treatment. Starting on day3, 16mg/kg (5Z) 
-7-Oxozeaenol or PBS (carrier solution) control, was 
intraperitoneally injected (i.p.) for every three days in each 
group of tumor bearing nude mice (n=5). After 7 times 
of injection, we found that there was ~70% reduction in 
tumor volume with (5Z) -7-Oxozeaenol treatment when 
compared with the PBS control on Day21 (*P=0. 049) 
(Figure 2H). Besides, the average tumor weight on Day21 
with (5Z) -7-Oxozeaenol injection was ~75% lower as 
compared with the PBS control group (*P=0. 015) (Figure 
2H). Altogether, these data further support the notion that 
overexpression of TAK1 contributes to ovarian cancer cell 
growth in vivo.
TAK1 promotes cell migration/invasion in vitro 
and in vivo of ovarian cancer cells
High cell proliferation, migration and invasion 
are salient features of aggressive high-grade ovarian 
tumors[25]. On the other hand, previous studies have 
shown that TAK1 is required for bone metastasis [26] 
and inhibition of TAK1 blocks cancer cell invasion and 
metastasis in breast cancer[27]. Hence, we postulated that 
TAK1 overexpression is able to promoting cell migration 
and invasion of ovarian cancer cells. Wound healing assay 
was firstly performed to examine the function of TAK1 
in the cell migration capacity of ovarian cancer cells. 
Upon treatment of Mitomycin C to exclude the factor of 
increased cell growth, we observed a faster wound closure 
rate in 429-C12 and 429-C13 by 1.4-fold and 1.3 fold, 
respectively, when compared to their vector controls 
(*P<0.01). Conversely, knockdown of endogenous TAK1 
Figure 3: TAK1 enhances ovarian cancer cell migration/invasion in vitro and in vivo. (A) Wound healing assay showed the 
over-expressed TAK1 exhibited a faster wound closure rate in 429-C12 and 429-C13 (*P<0.01), while knockdown of TAK1 exhibited 
a lower wound closure rate in SK-KD3 and SK-KD6 (*P<0.01) as compared with their vector controls. The arrows indicate the width 
of the wound and the relative cell migration rate is expressed as relative width of the wounds/time by bar charts. (B) Transwell cell 
invasion assay and the bar chart showed a higher invasive rate through Matrigel-coated membrane in TAK1 stably over-expressing clones 
(Acp-T2 and Acp-T3) (*P<0.01), while a lower invasive rate was observed in TAK1 knockdown clones SK-KD3 and SK-KD6 (*P<0.01) 
when compared to their vector controls. (C) Representative bioluminescence images on Day14 and Day30 of nude mice in PBS (carrier 
solution) group and TAK1 inhibitor ((5Z) -7-Oxozeaenol, 16mg/kg, 5 injections) group; PBS (carrier solution) group (n=3) presented 
significant higher relative bioluminescence index on Day30 as compared to the TAK1 inhibitor group (n=3), P=0.012; (D) Representative 
biofluorosence imaging of the livers. On Day30 for SKOV3 control group with PBS (carrier solution) and TAK1 inhibitor treatment group.
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in SK-sh1-KD3 and SK-sh1-KD6 significantly reduced 
the cell migration rate by 50% and 40%, respectively, as 
compared with their vector controls (*P<0.01) (Figure 
3A). Furthermore, using Transwell invasion assays, 
we demonstrated that there was a remarkable increase 
by 1.5-fold and 1.3-fold in cell invasion rate in Acp-T2 
and Acp-T3, respectively, as compared with vector 
controls (*P<0.01). In contrast, the numbers of cells 
invading through matrigel in Transwell invasion assays 
were significantly reduced in SK-sh1-KD3 and SK-sh1-
KD6 by 30% and 60%, respectively, as compared with 
vector controls (*P<0.01) (Figure 3B). To further confirm 
these functional roles of TAK1, a mouse model for in 
vivo study of ovarian cancer metastasis was conducted. 
The GFP-luminescence labelled SKOV3 cells (CMV-
GFP-T2A-Luciferase) were injected (intraperitoneally) 
i.p. into 6 nude mice. After 14 days, bioluminescence 
images were taken to record the start point (Figure 3C). 
Then the mice were separated into two groups; one group 
received intraperitoneal injections of TAK1 inhibitor, 
(5Z) -7-Oxozeaenol (16mg/kg), while the control group 
was injected with PBS only. After 5 injections, the 
bioluminescence imaging of the PBS group displayed 
prominent tumor size growth with an average 10-fold 
increase, whereas only 3.2-fold increase could be observed 
in the TAK1 inhibitor treated group on day 30 (*P=0.012) 
(Figure 3C). In addition, the livers of the mice were 
collected at the end of the experiment and examined with 
biofluorosence. Results showed that the livers in PBS 
group demonstrated stronger intensity of GFP signal as 
compared to the TAK1 inhibitor group, indicating that the 
TAK1 inhibitor could inhibit SKOV3 cells metastasized 
to livers of mice (Figure 3D). Taken together, these data 
suggest that inhibition of TAK1 activity is able to impair 
Figure 4: Inhibition of TAK1 sensitizes ovarian cancer cells to cisplatin-induced cell apoptosis. (A) XTT proliferation assay 
was performed to detect the effect of cisplatin on cell proliferation with ovarian cancer cells. The bar chart shows that TAK1 knockdown 
stable clones were more sensitive to cisplatin treatment as compared to vector control. Stable clones Acp-KD1 and Acp-KD10 were treated 
with 10mM cisplatin for 48h (*P<0.01), and SK-KD3 and SK-KD6 were treated with 5mM cisplatin for 48h (C3, *P=0. 028). (B) The 
bar chart showed that TAK1 inhibitor, (5Z)-7-Oxozeaenol (5µM), could sensitize ovarian cancer A2780cp (*P<0.05) (cisplatin: 10mM) 
and ES-2 (*P<0.01) (cisplatin: 3.5mM) to cisplatin-induced cell apoptosis. The results were obtained from XTT cell proliferation assay 
in a 48-hour time course. (C) Focus formation assay was performed and showed that TAK1 inhibitor, (5Z) -7-Oxozeaenol (2µM), could 
sensitize ovarian cancer A2780cp (*P<0.01) (cisplatin: 7.5mM) and ES-2 (*P<0.01) (cisplatin: 2mM) to cisplatin-induced cell apoptosis 
as compared with their controls or each single treatment. Representative photos were taken to show the number and size of the colonies. 
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in vitro and in vivo ovarian cancer cell motility and 
metastasis.
TAK1 sensitizes ovarian cancer cells to cisplatin-
induced cytotoxicity
Previous studies have reported that TAK1 increases 
chemoresistance via the NF-κB pathway and targeting 
TAK1 has been shown to be a potential therapeutic 
approach to reducing the chemoresistance of pancreatic 
cancer [16, 28]. However, the functional role of TAK1 
in ovarian cancer chemoresistance is unknown. To 
define whether inhibition of TAK1 can sensitize ovarian 
cancer cells to cisplatin-induced cell apoptosis, XTT 
cell proliferation assay was performed in the TAK1 
knockdown clones SK-sh1-KD3, SK-sh1-KD6, Acp-sh1-
KD1 and Acp-sh2-KD10. Notably, treatment of TAK1-
depleted A2780cp clones (Acp-sh1-KD1 and Acp-sh2-
KD10) with cisplatin (MERK MILLIPORE, Billerica, 
MA; dissolved in DMSO), and TAK1-depleted SKOV3 
clones (SK-sh1-KD3 and SK-sh1-KD6) with cisplatin 
led to a remarkable decrease in cell viability by 60% and 
40% in Acp-sh1-KD1 and Acp-sh2-KD10, respectively 
(**P<0.01), and 40% in SK-sh1-KD3 (*P=0.028) as 
compared to their vector controls (Figure 4A). In addition, 
(5Z)-7-Oxozeaenol co-treatment with cisplatin decreased 
the cell viability of A2780cp and ES-2, which express 
high levels of TAK1 by 25% and 50%, respectively 
(*P<0.01) (Figure 4B). Moreover, focus formation assay 
confirmed that co-treatment of (5Z) -7-Oxozeaenol could 
cause less number and smaller size of colonies in both cell 
lines treated with cisplatin (*P<0.01) (Figure 4C). These 
findings confirm that the upregulation of TAK1 is involved 
in cisplatin-resistance of ovarian cancer cells.
Figure 5: TAK1 exerts its functional effects through activation of NF -κB pathways by phosphorylation at Ser412. (A) 
Western blot analysis demonstrated that p-TAK1 at Thr184/187 was just found in HEK293 and Hela cells only, while p-TAK1 at Ser412 was 
generally found in all cell types including ovarian cancer cell lines (n=4). (B) Western blot analysis showed the phosphorylation of p-TAK1 
(Ser412) was increased concomitantly with p-IKK (Ser180/181) and p-IκB (Ser32/36) as upon treatment of TAK1 activator, PGE2, in 
ovarian cancer cells, whereas treatment with TAK1 inhibitor, (5Z) -7-Oxozeaenol, completely diminished the phosphorylation of p-TAK1 
(Ser412), p-IKK (Ser180/181) and p-IκB (Ser32/36) concentration dependently. The level of IκBα was reduced by PGE2 and increased 
upon treatment of (5Z) -7-Oxozeaenol. Cells were treated by PGE2 or (5Z)-7-Oxozeaenol for 24 hours before harvested for Western 
blotting. The protein amount of loading was normalized by β-actin. (C) NF-κB luciferase reporter assay showed that TAK1 increased the 
luciferase activity of NF-κB in A2780cp concentration dependently (**P<0.01). Co-treatment of TAK1 inhibitor, (5Z) -7-Oxozeaenol 
(2.5 µM and 5.0 µM for 24 hours), decreased the luciferase activity of NF-κB in TAK1 transfected A2780cp cells (*P<0.01). (D) Upon 
treatment of PGE2 (1.4 µM), the point mutations at Ser412 of TAK1 had the similar expression level of TAK1 protein as wild type TAK1, 
however, the phosphorylation of p-TAK1 (Ser412) was totally abrogated. The protein amount of loading was normalized by β-actin. The 
above experiments were performed thrice independently. (E) TAK1 in vitro kinase assay. The pcDNA/Flag-TAK1 and pcDNA/Flag-
mutTAK1 were transfected into A2780cp cells respectively. After 48 hours, Human IL-1α (10ng/ml) was used to treat the transfected cells 
with various time points. Both wild-type and mutant TAK1 were immunopreciptated (IP) from cell lysates, and TAK1 kinase activity was 
examined by evaluating the level of Phospho-MKK6 using immunoblotting (IB). The input of total MKK6 and Flag/TAK1 or Flag/mutant 
TAK1 were checked by immunoblotting using anti-MKK6 and anti-Flag respectively.
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Ser412 phosphorylation is required for TAK1 to 
activate NF-κB signaling in ovarian cancer 
Since TAK1 was confirmed to be upregulated in 
ovarian cancer and its level well correlated with tumor 
progression, the molecular mechanism of TAK1 action 
deserves further investigation. The downstream effects 
of TAK1 are mediated via phosphorylation of multiple 
residues in its activation loop [18]. Our western blot 
analysis revealed that thephosphorylation of p-TAK1 
(Thr184/187) was very low, whereas the phosphorylation 
of p-TAK1 (Ser412) was dominately expressed in all the 
ovarian cancer cell lines (Figure 5A). It has previously 
been reported that the NF-κB pathway is implicated in 
the regulation of cell migration and invasion [11, 12]. 
Since TAK1 takes many functional roles in ovarian cancer 
progression such as cell proliferation, migration/invasion 
and importantly, Kobayashi et al. has reported that the 
phosphorylation of the Ser412 residue in TAK1 could 
activate NF-κB through induction of IκBα degradation 
[21]. Therefore, we hypothesized that NF-κB signaling 
might also be activated by TAK1 via PKA-pathway 
mediated IκBα degradation in ovarian cancer cells. As 
expected, our western blot results showed that PGE2 
could increase the phosphorylation of Ser412 in TAK1 
that in turn, elevated the phosphorylation of p-IKK 
(Ser176/180) and p-IκB (Ser32/36), and reduced the 
level of IκBα in A2780cp cells (Figure 5B). Conversely, 
treatment of A2780cp cells with the TAK1 inhibitor (5Z) 
-7-Oxozeaenol showed an opposite results to the use of 
PGE2 (Figure 5B). In addition, using NF-κB luciferase 
reporter assay, NF-κB signaling activity was shown to 
increase from 1.2-fold to 2-fold when A2780cp cells were 
transiently transfected with the TAK1-expressing plasmid 
pCMV-HA-TAK from 0 ng to 200 ng (*P<0.01) (Figure 
5C). In contrast, NF-κB signaling activity in A2780cp 
cells was reduced by 60% to 65% upon treatment with 
(5Z) -7-Oxozeaenol from 0 M to 5.0 µM (*P<0.01) 
(Figure 5C).
To better understand whether phosphorylation at 
Ser412 is critically required for TAK1 function, a mutant 
TAK1 plasmid (pCDH-TAK1-mut) was generated by 
PCR-based site-directed mutagenesis the Ser412→Ala 
mutant TAK1 (Supplementary Figure S2) [21]. Western 
Figure 6: Mutation at Ser412 of TAK1 completely abrogates its function in ovarian cancer aggressiveness. (A) XTT cell 
proliferation assay, (B) focus formation, (C) Transwell migration, and (D) Transwell invasion assays demonstrated that the point mutation 
at Ser412 completely impaired the functional effects of TAK1 in promoting cell growth, cell migration and invasion as compared with 
wild-type TAK1 overexpressing A2780cp cells (T2) (*P<0.05).
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blot analysis confirmed that ectopic expression of the 
pCDH-TAK1-mut plasmid in A2780cp cells could not 
increase phosphorylation at Ser412 of TAK1 but had two-
fold less of the phosphorylation of p-IKK (Ser176/180) 
than that of using the wild-type TAK1 plasmid upon 
treatment of PGE2 (1.4µM) (Figure 5D). 
Accumulating evidence has suggested that TAK1 
forms a complex with TAB1 and TAB2/3 at N- and 
C-termini respectively (Supplementary Figure S2) 
[29, 30], we questioned whether the phosphorylation 
at Ser412 residue in TAK1 could modulate the kinase 
activity of TAK1. Hence, we performed in vitro kinase 
assay for TAK1 activity according to Yang et al [28]. 
Upon induction of IL-1α in A2780cp transfected with 
the wild-type TAK1 palsmid (pcDNA/Flag-TAK1) and 
the mutant TAK1 plasmid (pcDNA/Flag-mutTAK1), the 
immunoprecipitated wild-type TAK1 could remarkably 
phosphorylate its downstream target, MKK6, while the 
immunoprecipitated mutant TAK1 had relatively lower 
capacity in phosphorylation of MKK6 (Figure 5E). This 
infers that the phosphorylation of TAK1 at Ser412 increase 
the kinase activity of TAK1 in ovarian cancer cells. 
Furthermore, pCDH-TAK1-Mut, when stably transfected 
into A2780cp, could not exert any increased higher 
capacities in cell proliferation, migration and invasion 
when compared with vector controls or as same as wild-
type TAK1 overexpressing cells (Figure 6A-D). These 
data give the first report that phosphorylation of TAK1 
at Ser412, instead of Thr184/187, is critically required 
for activation of the NF-κB pathway and its oncogenic 
properties.
DISCUSSION
Recent studies have revealed that the personalized 
gene-targeted. cancer therapy shows promising results 
in improving the survival and quality of life of patients 
suffering advanced-stage and high-grade tumors [4-
7]. Therefore, a better understanding of molecular 
mechanisms underlying ovarian cancer oncogenesis is 
urgently needed for developing this therapeutic approach. 
In this study, we have provided overwhelming evidence 
that TAK1 plays an oncogenic role in promoting cell 
proliferation, anchorage-independent growth ability, 
cell migration/invasion, and chemoresistance, as well 
as tumor growth/metastasis of ovarian cancer cells in 
both in vitro and in vivo models. Our findings indicate 
that TAK1 was significantly overexpressed in ovarian 
cancers, in particular high-grade and metastatic tumors. 
More importantly, we identify phosphorylation at Ser412 
is critically required for TAK1 in activating of NF-κB 
activity and its tumorigenic capacities in ovarian cancer 
cells.
Previous studies have reported that the increased 
NF-κB activity is involved in metastatic serous ovarian 
carcinoma and targeting NF-κB pathway is a promising 
therapeutic approach to high-grade metastatic ovarian 
cancer [31, 32]. This indicates that NF-κB signaling 
acts as a master regulator in aggressive ovarian cancers. 
However, there is a lack of studies showing the upstream 
regulation of NF-κB signaling in carcinogenesis. In this 
study, we have revealed that TAK1 is frequently found in 
high-grade tumors with metastatic tendency, suggesting 
that TAK1 shares similar functional properties as the NF-
κB pathway in aggressive human cancers. On the other 
hand, previous studies have documented that TAK1 can 
upregulate the NF-κB signaling which in turn increases the 
chemoresistance of human cancers [28, 33, 34]. Hence, we 
postulate that TAK1 promotes ovarian cancer cell growth, 
cell migration and invasion, as well as cisplatin-resistance 
via modulation of NF-κB signaling. Indeed, our results 
using Western blotting and NF-κB promoter luciferase 
assays clearly show that TAK1 is able to modulate NF-κB 
signaling activity, whereas either co-treatment with TAK1 
inhibitor, (5Z) -7-Oxozeaenol, or shRNA-mediated TAK1 
knockdown abrogates TAK1’s effect on NF-κB signaling 
activity in ovarian cancer cells. 
TAK1 is a mitogen-activated protein kinase 
kinase kinase that can be activated by various upstream 
cytokines through formation of a protein-signaling 
complex which consists of a variety of proteins such as 
TAB1, TAB2/3 and TRAFs [35]. Thus, TAK1 can exert 
distinct functions in different cell types depending on 
the nature of the upstream inducing signals [35] This 
makes TAK1 a double-edged sword in different types of 
human cancers [36]. For instance, suppression of TAK1 
is required to promote prostate cancer tumorgenesis [37], 
while activation of TAK1 leads to hepatocyte apoptosis 
in liver cancer through activation of JNK signaling and 
NF-κB-independent function of NEMO, indicating that 
TAK1 is a tumor suppressor in some subtypes of human 
cancers [14, 37, 38]. On the other hand, TAK1 has been 
shown to enhance oncogenic capacities in liver cancer, 
lung cancer, pancreatic cancer and head and neck cancer 
via activation of the NF-κB pathway [26, 33, 39-41]. 
These evidences suggest that TAK1 plays dual roles in 
oncogenesis; tumor suppressor and oncogene, depending 
on the downstream signaling pathway that is activated and 
therefore dominating in a particular cancer cell type. In 
this study, we have demonstrated that NF-κB signaling 
is indispensable for TAK1 function in ovarian cancer 
cells. It is well known that the phosphorylation of TAK1 
can subsequently activate IKK leading to the activation 
of NF-κB [14] and in cell metastasis of breast and renal 
cell cancers [26, 42]. In fact, using the TAK1 inhibitor 
(5Z) -7-Oxozeaenol, as well as gain- and loss-of-function 
genetic modifications of TAK1, we have provided strong 
evidences to support that TAK1 is required for NF-κB 
activation in ovarian cancer. Hence, these findings point 
to TAK1 being an oncogenic gatekeeper for NF-κB 
signaling, which is a key signaling pathway in governing 
ovarian cancer tumorigenesis.
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It has been demonstrated that TAK1 kinase activity 
is regulated by multiple post-translational modifications 
of TAK1 and TABs [43]. Many phosphorylation 
sites had been identified previously, such as Ser192, 
Thr178, Thr184/187 and Ser412 [18-21]. Ser192 
autophosphorylaion was first identified to be involved in 
IL-1 induced activation of NF-κB through the interaction 
of TAB1 at N-terminus of TAK1 kinase domain [18]. 
Dual phosphorlation of Thr178 and Thr184 was required 
for IL-1- and IL-6-mediated activation of both the NF-
κB and JNK pathways [19]. In this study, we have 
surprisingly found that Thr184/187 of TAK1 is not the 
core phosphorylated sites in ovarian cancer cells. Instead, 
we identify the phosphorylation site at the Ser412 residue 
as being critically required for TAK1 in mediating NF-
κB activity in ovarian cancer cells. Although the Ser412 
residue is not in the kinase domain of TAK1, it has been 
shown to be interacted with TAB2 at the C-terminus of 
TAK1 and could be phosphorylated by PKA pathway 
[21]. cAMP/PKA signaling is an oncogenic signaling 
and is involved in ovarian cancer progression [44] [45]. 
Importantly, cAMP/PKA signaling has been reported to 
promote NF-κB activity[46, 47]. Indeed, in consistent 
with the previous finding of Kabayashi et al. [21], our 
data showed that the increased phosphorylation of Ser412 
by treatment of PGE2 led to the increased degradation 
of IκBα (elevated p-IκB (Ser32/36)) and increased 
phoshphorylation of p-IKK (Ser176/180) (NF-κB activity). 
This has been further confirmed using NF-kB luciferase 
reporter assay. In contrast, mutation by Ser412→Ala 
aboragated the capacity of TAK1 in promoting NF-κB 
activity as well as its associated oncogenic properties in 
ovarian cancer cells. On the other hand, it has been shown 
that the phosphorylation of TAK1 Ser412 by PKA may 
influence the signaling complex formation (TAK1-TAB1-
TAB2/TAB3) induced by the various ligands including 
IL-1α in Ser192 of TAK1 [18, 21]. To examine whether 
the phosphorylation of Ser412 affects the complex 
confirmation as well as the kinase activity of TAK1, an in 
vitro TAK1 kinase was performed to examine the capacity 
of the wild-type or the Ser412 mutant TAK1 in modulating 
TAK1 activity under IL-1α induction. As expected, we 
found that Ser412 phosphorylation has not only activated 
NF-κB through degradation of IκBα but also alters IL-
1α-induced TAK1 activity. However, we still don’t know 
how the phosphorylation of Ser412 affects the signaling 
complex formation (TAK1-TAB1-TAB2/TAB3) and the 
kinase activity. Hence, further study in examining the 
underlying mechanism is warranted. However, to the best 
of our knowledge, this is the first report showing that the 
phosphorylation of Ser412 residue in TAK1 is essential for 
the activation of NF-κB signaling in ovarian cancer cells.
In conclusion, our findings suggest that the 
upregulation of TAK1 and the phosphorylation at 
Ser412 residue in TAK1 is required for enhancing NF-
κB-dependent oncogenic capacities in aggressive high-
grade ovarian cancer. Therefore, targeting TAK1 may 
be a potential therapeutic approach in the personalized 
molecular therapy in ovarian cancer.
MATERIALS AND METHODS
Ovarian cancer samples and cell lines
A total of 88 tumor samples surgically resected 
from primary ovarian cancer patients and 48 normal ovary 
samples from benign diseases were randomly selected for 
this study. The histologic subtypes and disease stages 
of the tumors were classified according to International 
Federation of Gynecology and Obstetrics criteria. The 
use of clinical specimens was approved by the local 
institutional ethics committee (IRB no. UW11-298). Four 
ovarian cancer cell lines (high-grade serous subtype); 
A2780cp, (kindly provided from Professor Benjamin 
Tsang, The University of Ottawa), SKOV3 and OVCA429 
(ATCC, Rockville, MD, USA) [48], one ovarian cancer 
cell line (clear cell subtype), ES-2, (ATCC), as well as 
HEK293 cells were cultured in Dulbecco’s modified 
Eagle medium (DMEM) (Gibco-BRL, Gaithersburg, 
MD) with 10% Fetal Bovine Serum (FBS) (Gibco-BRL, 
Gaithersburg, MD), penicillin and streptomycin (100 
units/ml) at 370C in incubator with 5% CO2. The cell line 
authentication was done by in-house STR DNA profiling 
analysis. Two pairs of primary cultured cells from the 
same patients from both omentum (OMC) and ovaries 
(OVC) were obtained in Queen Mary Hospital under 
human ethics (HKU/HA HKW IRB number: UW 11-
298). The primary culture cells were incubated with a mix 
medium of MCD (Invitrogen) and 199 (Invitrogen) with 
a proportion of 1:1. All the experiments were performed 
after 10 days incubation.
Plasmids and Cell Transfection
Stable TAK1-overexpressing clones were generated 
by either transfection of pCMV-HA-TAK (kindly provided 
by Kuni Matsymoto Lab, Acp-T2 and Acp-T3) or pCDH- 
Tag-1-TAK1 lentiviral plasmid (429-C12 and 429-C13) 
constructed by PCR amplification of the TAK1 ORF from 
pCMV-HA-TAK followed by subcloning into the pCDH-
CMV-MCS-EF1-copGFP (SBI). TAK1 shRNAi constructs 
(HuSHTM Company, Japan) were used to knockdown 
endogenous TAK1 in TAK1-overexpressing ovarian 
cancer cell lines. Stable mutant Ser412 TAK1 clones 
were generated by transfection of A2780cp cells with 
the pCDH-TAK1-mut plasmid, which was constructed 
by PCR-based site-directed mutagenesis of Ser 412 to 
Ala 412 using designed primers according to Kobayashi 
et al. [21]. GFP-luminescence labeled stable clones were 
generated by lenti-virus transfection of Lenti-reporter 
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plasmid, CMV-GFP-T2A-Luciferase (BLIV101PA-1) 
(System Biosciences, Mountain view, CA).
Quantitative Reverse Transcription-Polymerase 
Chain Reaction (qPCR)
qPCR was performed using the oligonucleotides/
TagMan probes provided for TagMan Gene Expression 
Assays (Applied Biosystems, Foster City, CA) (TAK1, 
Assay ID: HS01105682_m1; 18S, Catalog Number: 
4310893E) in an ABI 7500 system according to the 
manufacture’s instruction. Expression levels of target 
genes were quantified against endogenous 18S level 
using the comparative CT method. The 7500 System SDS 
Software was used for data analysis.
Western blot and Immunohistochemical (IHC) 
analyses
For Western blot analysis, cells were lysed with 
cell lysis buffer (Cell Signaling Technology, Danvers, 
MA) containing protease inhibitor cocktail (Roche, 
Indianapolis, IN) and phenylmethylsulfonyl fluoride 
(Sigma, St. Louis, MO). Samples were resolved by SDS-
PAGE and electroblotted onto Immobilon-P Transfer 
Membrane (Merk Millipore, Billerica, MA). Blots were 
blocked with 5% skim milk, followed by incubation 
with antibodies against TAK1, Phospho-TAK1 (Ser412), 
Phospho-TAK1 (Thr184/187), Phospho-IKKα/β 
(Ser180/181), IKK, Phospho- IκBα (Ser32/36), IκBα, 
Phospho-MKK3 (Ser189)/MKK6 (Ser207) (Cell Signaling 
Technology, Danvers, MA); MKK6 (R&D Systems, 
Minneapolis, MN); GFP (Santa Cruz Biotechnology, 
Santa Cruz, CA) or β-actin (Sigma, St. Louis, MO). 
Blots were then incubated with goat anti-rabbit or anti-
mouse secondary antibodies that are conjugated with 
horseradish peroxidase (Amersham Pharmacia Biotech, 
Piscataway, NJ) and signals visualized by enhanced 
chemiluminescence .
Immunohistochemical staining for TAK1 was 
performed on an ovarian cancer tissue array (OVC1021; 
Pantomics, Inc.). The section was immunostained with 
primary polyclonal anti-TAK1 antibody (Cell signaling 
Technology, Danvers, MA, USA) in 1:50 dilution. For 
negative controls, the primary antibody was replaced 
with TBS. The immunoreactivity score for each case was 
calculated as previously protocol [49].
Luciferase reporter assay
Luciferase Reporter Assay was performed using the 
DLR Assay kit (Promega, Madison, WI) according to the 
manufacturer’s instructions. Cells were cultured on 6-well 
plates and were transfected with plasmids two days before 
the luciferase assay.
In vitro Kinase assay
To examine the TAK1 activity, an in vitro kinase 
assay was modified from Yang et al. [28]. The wild 
type TAK1 and mutant TAK1 from pCMV-HA-TAK 
and pCDH-TAK1-mut plasmids were subcloned into 
pcDNA3.1(+)/3xFlag vector to generate pcDNA/Flag-
TAK1 and pcDNA/Flag-mutTAK1. Both plasmids were 
transfected into A2780cp cells, respectively an cell 
lysates were harvested after 48 hours and treated with 
Human IL-1α (Peprotech, Rocky Hill, NJ). Cell lysates 
were prepared by Cell Lysis Buffer (Cell Signaling) and 
immunoprecipitated with anti-Flag (Sigma) followed by 
overnight incubation with protein A/G-conjugated beads 
(Santa Cruz) at 40C. After 3 times of washing using Cell 
Lysis Buffer, an in vitro kinase reaction was performed at 
30°C for 90 min in 20 µl Kinase Buffer (Cell Signaling) 
containing ATP (200µM) and 1 µg of unactive MKK6/
SKK3 protein (Millipore, Billerica, MA). The activities of 
wild type TAK1 and mutant TAK1 were determined by the 
levels of phospho-MKK6 using Western blotting. 
In vitro functional assays 
Cell proliferation kit (XTT) (Roche, Indianapolis, 
IN, USA) was used to measure cell viability according 
to the manufacturer’s manual [50]. Focus formation 
assay was performed as a more long-term proliferation 
assay and soft agar assay was performed to detect cell 
anchorage-independent growth ability. Wound healing 
assay and a Cell Migration Assay kit (MILLIPORE, 
Cat. No. ECM508) were used to detect cell migration 
ability. Quantification of cell invasion was performed 
using QCM™ 24-Well Colorimetric Cell Invasion Assay 
Kit (Chemicon International, Temecula, CA, USA). All 
experiments were done in triplicates and results were 
presented as the mean ± SD.
Tumor xenograft mouse model
A2780cp-sh1-KD1 and its scrambled control cells 
at a concentration of 1×106 cells/100µl were injected 
subcutaneously into 5-week female BALB/c nude mice. 
For Acp-sh1-KD1 and vector control injection, tumor 
formation in nude mice (n=5) was monitored for every 3 
days since Day 3. For the A2780cp cell injection group, 
the TAK1 inhibitor, (5Z) -7-Oxozeaenol (16mg/kg) 
(Sigma) (in carrier solution which consists of 10% DMSO 
in PBS), was injected into the mice in peritoneal every 
three days., was administered by intraperitoneal (i.p.) 
injections for every two days with total of 7 injections 
into five mice from Day 3. As a control group, the carrier 
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solution only was administrated i.p. for the same time 
of treatment. Tumor sizes were measured using slide 
calipers and were calculated by the following formula: 
volume = (width) 2 x length x π/6. Tumor growth curves 
were plotted from the mean volume±SEM of tumors from 
5 mice. Side effects such as body weight changes were 
monitored closely. For in vivo mouse model of metastasis, 
the pure GFP-luminescence tagged SKOV3 cells (1×106 
cells/100 µl) were mixed with 100 µl Matrigel Matrix (BD 
Biosciences, San Jose, CA) and intraperitoneally injected 
into 6 nude mice. TAK1 inhibitor, (5Z) -7-Oxozeaenol 
(16mg/kg) (in carrier solution), was administered i.p. for 
every three days with total 5 injections into 3 mice. For the 
control group, the carrier solution was injected i.p. only. 
The ovarian cancer cells (with GFP-labelled) metastasized 
to livers of mice were analyzed by biofluorscence imaging. 
Both bioluminescence and biofluorescence imagings 
were performed using the Xenogen IVIS 100 system and 
analyzed using Living Imaging(R), version 2.50.1. All the 
animal experiments were approved by the University of 
Hong Kong Committee on the Use of Live Animals in 
Teaching and Research (CULATR No. 2053-09).
Statistical analysis
Receiver operating characteristic (ROC) curve was 
used to determine cut-off points for qPCR and IHC results. 
The clinicopathological analysis between the expression of 
TAK1 and clinical parameters was analyzed by Crosstabs 
and Pearson Chi-Square test. The Student’s t-test was used 
to analyze cell viability, migration/invasion and in vivo 
tumor growth results. Statistical analyses were performed 
using the SPSS 13.0 software (SPSS). P-values of less 
than 0.05 were considered significant in all tests. All data 
were expressed as mean ± SD.
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